electroCore Q1 revenue $9.6M (+43% YoY); reaffirms ~30% FY2026 growth guidance

electroCore, Inc.

2026-Q1 EPS reported -$0.59 revenue$9,584,000

Net sales $9.6M, record quarterly revenue, up 43% from $6.7M Q1 2025.
GAAP net loss $5.3M ($0.59 per share); includes $1.9M leadership transition expenses.
Adjusted EBITDA net loss improved 24% YoY to $2.3M from $3.1M.
VA prescription gammaCore revenue grew 26% YoY; Quell Fibromyalgia quarterly sales >$1M.
Michael Fox appointed COO in April 2026; Truvaga launched in UK in January 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

electroCore, Inc. reported first quarter ended March 31, 2026 results: revenue $9.6 million, net income $5.3 million. Guidance reaffirmed.

Period: first quarter ended March 31, 2026
Revenue: $9.6 million
Net income: $5.3 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

The information contained in this Item 2.02 and --- EX-99.1 (EX-99.1) --- electroCore Announces First Quarter 2026 Financial Results First quarter 2026 net sales of $9.6 million, an increase of 43% over $6.7 million in the first quarter 2025 Net loss of $5.3 million with Adjusted EBITDA net loss improving 24% from prior-year period to $2.3 million

View on SEC.gov

Browse all earnings releases →

electroCore, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-021493

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.